Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samfenet Plus Chemotherapy in HER2-positive Solid Tumors
NCT04215159Phase 2Unknown
- Start
- Dec 2019
- Primary completion
- Dec 2019
01
Overview
Phase 2, open-label, single-arm trial in solid tumor. Primary endpoint: Objective Response Rate at 8 weeks. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04215159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215159.